919 related articles for article (PubMed ID: 31025557)
1. Clinical outcomes of non-alcoholic fatty liver disease: Polish-case control study.
Kempiński R; Łukawska A; Krzyżanowski F; Ślósarz D; Poniewierka E
Adv Clin Exp Med; 2019 Dec; 28(12):1615-1620. PubMed ID: 31025557
[TBL] [Abstract][Full Text] [Related]
2. Obesity and metabolic syndrome as risk factors for the development of non-alcoholic fatty liver disease as diagnosed by ultrasound.
Petrović G; Bjelaković G; Benedeto-Stojanov D; Nagorni A; Brzački V; Marković-Živković B
Vojnosanit Pregl; 2016 Oct; 73(10):910-20. PubMed ID: 29327896
[TBL] [Abstract][Full Text] [Related]
3. Clinical Characteristics and Metabolic Profiles of Non-Alcoholic Fatty Liver Disease (NAFLD) in Lean Patients and Their Comparison with Obese and Overweight NAFLD.
Chakrabarty M; Jha AN; Sharma DJ
J Assoc Physicians India; 2022 Apr; 70(4):11-12. PubMed ID: 35443531
[TBL] [Abstract][Full Text] [Related]
4. Non-alcoholic fatty liver disease patients attending two metropolitan hospitals in Melbourne, Australia: high risk status and low prevalence.
George ES; Roberts SK; Nicoll AJ; Reddy A; Paris T; Itsiopoulos C; Tierney AC
Intern Med J; 2018 Nov; 48(11):1369-1376. PubMed ID: 29845719
[TBL] [Abstract][Full Text] [Related]
5. [Prevalence and clinical features of non-alcoholic steatohepatitis in a hypertensive population].
García-Carretero R; Barquero-Pérez O; Mora-Jiménez I; Soguero-Ruiz C; Goya-Esteban R; Rodríguez-Castro C; Ramos-López J
Hipertens Riesgo Vasc; 2019; 36(3):130-136. PubMed ID: 30655210
[TBL] [Abstract][Full Text] [Related]
6. Colonic Diverticulosis and Non-Alcoholic Fatty Liver Disease: Is There a Connection?
Pantic I; Lugonja S; Rajovic N; Dumic I; Milovanovic T
Medicina (Kaunas); 2021 Dec; 58(1):. PubMed ID: 35056346
[No Abstract] [Full Text] [Related]
7. The association of non-alcoholic fatty liver disease and metabolic syndrome in a Chinese population.
Lee SW; Lee TY; Yang SS; Peng YC; Yeh HZ; Chang CS
Hepatobiliary Pancreat Dis Int; 2017 Apr; 16(2):176-180. PubMed ID: 28381382
[TBL] [Abstract][Full Text] [Related]
8. Prevalence and Predictors of Non-Alcoholic Fatty Liver Disease in Morbidly Obese South Indian Patients Undergoing Bariatric Surgery.
Praveenraj P; Gomes RM; Kumar S; Karthikeyan P; Shankar A; Parthasarathi R; Senthilnathan P; Rajapandian S; Palanivelu C
Obes Surg; 2015 Nov; 25(11):2078-87. PubMed ID: 25835982
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of and predictive factors for nonalcoholic fatty liver disease in Sudanese individuals with type 2 diabetes: Is metabolic syndrome the culprit?
Almobarak AO; Barakat S; Suliman EA; Elmadhoun WM; Mohamed NA; Abobaker IO; Noor SK; Bushara SO; Ahmed MH
Arab J Gastroenterol; 2015 Jun; 16(2):54-8. PubMed ID: 26174761
[TBL] [Abstract][Full Text] [Related]
10. Evaluating the Relationship Between Metabolic Syndrome and Liver Biopsy-Proven Non-Alcoholic Steatohepatitis in China: A Multicenter Cross-Sectional Study Design.
Xu ZJ; Shi JP; Yu DR; Zhu LJ; Jia JD; Fan JG
Adv Ther; 2016 Nov; 33(11):2069-2081. PubMed ID: 27743352
[TBL] [Abstract][Full Text] [Related]
11. Relationship between ultrasound features of nonalcoholic fatty liver disease and cardiometabolic risk factors in patients with newly diagnosed type 2 diabetes.
Kosmalski M; Kasznicki J; Drzewoski J
Pol Arch Med Wewn; 2013; 123(9):436-42. PubMed ID: 23792440
[TBL] [Abstract][Full Text] [Related]
12. Non-alcoholic fatty liver disease, insulin resistance, metabolic syndrome and their association with vascular risk.
Muzurović E; Mikhailidis DP; Mantzoros C
Metabolism; 2021 Jun; 119():154770. PubMed ID: 33864798
[TBL] [Abstract][Full Text] [Related]
13. Both alcoholic and non-alcoholic steatohepatitis association with cardiovascular risk and liver fibrosis.
Sánchez-Jiménez BA; Brizuela-Alcántara D; Ramos-Ostos MH; Alva-López LF; Uribe-Esquivel M; Chávez-Tapia NC
Alcohol; 2018 Jun; 69():63-67. PubMed ID: 29660603
[TBL] [Abstract][Full Text] [Related]
14. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030.
Estes C; Anstee QM; Arias-Loste MT; Bantel H; Bellentani S; Caballeria J; Colombo M; Craxi A; Crespo J; Day CP; Eguchi Y; Geier A; Kondili LA; Kroy DC; Lazarus JV; Loomba R; Manns MP; Marchesini G; Nakajima A; Negro F; Petta S; Ratziu V; Romero-Gomez M; Sanyal A; Schattenberg JM; Tacke F; Tanaka J; Trautwein C; Wei L; Zeuzem S; Razavi H
J Hepatol; 2018 Oct; 69(4):896-904. PubMed ID: 29886156
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data.
Kabbany MN; Conjeevaram Selvakumar PK; Watt K; Lopez R; Akras Z; Zein N; Carey W; Alkhouri N
Am J Gastroenterol; 2017 Apr; 112(4):581-587. PubMed ID: 28195177
[TBL] [Abstract][Full Text] [Related]
16. Prevalence and Specific Manifestations of Non-alcoholic Fatty Liver Disease (NAFLD) and Diabetes Mellitus Type 2 Association in a Moroccan Population: A Cross-sectional Study.
Assarrar I; Messaoudi N; Ongoth FEM; Abdellaoui W; Malki A; Rouf S; Abda N; Ismaili Z; Latrech H
Rev Diabet Stud; 2022 Sep; 18(3):140-145. PubMed ID: 36309775
[No Abstract] [Full Text] [Related]
17. Association between the CYBA and NOX4 genes of NADPH oxidase and its relationship with metabolic syndrome in non-alcoholic fatty liver disease in Brazilian population.
Rabelo F; Stefano JT; Cavaleiro AM; Lima RVC; de Campos Mazo DF; Carrilho FJ; Correa-Giannella ML; Oliveira CP
Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):330-335. PubMed ID: 30087027
[TBL] [Abstract][Full Text] [Related]
18. [Prevalence and harm of nonalcoholic fatty liver disease].
Shao YL; Fan JG
Zhonghua Gan Zang Bing Za Zhi; 2019 Jan; 27(1):10-13. PubMed ID: 30685917
[TBL] [Abstract][Full Text] [Related]
19. Comparison of clinical and metabolic profiles of lean versus non-lean nonalcoholic fatty liver disease.
Navarroza AMC; Wong SN
Indian J Gastroenterol; 2021 Aug; 40(4):380-388. PubMed ID: 34213749
[TBL] [Abstract][Full Text] [Related]
20. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
Athyros VG; Alexandrides TK; Bilianou H; Cholongitas E; Doumas M; Ganotakis ES; Goudevenos J; Elisaf MS; Germanidis G; Giouleme O; Karagiannis A; Karvounis C; Katsiki N; Kotsis V; Kountouras J; Liberopoulos E; Pitsavos C; Polyzos S; Rallidis LS; Richter D; Tsapas AG; Tselepis AD; Tsioufis K; Tziomalos K; Tzotzas T; Vasiliadis TG; Vlachopoulos C; Mikhailidis DP; Mantzoros C
Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
